Table 1 Clinical features of the participants who contributed plasma
Characteristics | RA | OA | HC |
|---|---|---|---|
Number of participants | 30 | 30 | 30 |
Sex, male/female | 8/22 | 7/23 | 13/17 |
Age, mean (range) | 60.1 (22 to 77) | 75.1 (65 to 89) | 46.5 (32 to 62) |
Disease duration (y), mean (range) | 10.4 (0.3 to 32) | NA | NA |
Positive anti-CCP antibody, n (%) | 10 (90.9%)†| NA | NA |
ESR (mm), mean (range) | 37.2 (4 to 116) | NA | NA |
CRP (mg/dl), mean (range) | 2.1 (0 to 9.6) | NA | NA |
MMP3 (ng/ml), mean (range) | 290.1 (32.4 to 800) | NA | NA |
DAS28, mean (range) | 4.4 (1.7 to 7.1) | NA | NA |
   SJC, mean (range) | 4.3 (0 to 13) | NA | NA |
   TJC, mean (range) | 4.5 (0 to 27) | NA | NA |
VAS | 42.3 (0 to 95) | NA | NA |
Steinbrocker Stage, n | I: 4, II: 3, III: 6, IV: 17 | NA | NA |
Steinbrocker Class, n | I: 1, II: 24, III: 5, IV: 0 | NA | NA |
Kellgren/Lawrence grade, n | NA | I: 0, II: 0, III: 9, IV: 21 | NA |
Medication, n (%) | Â | Â | Â |
   Prednisolone | 21 (70%) | NA | NA |
   Methotrexate | 18 (60%) | NA | NA |
   Infliximab | 8 (27%) | NA | NA |
   Eternercept | 2 (6.7%) | NA | NA |
   Tocilizumab | 2 (6.7%) | NA | NA |
   Tacrolimus | 2 (6.7%) | NA | NA |
   Salazosulfapyridine | 6 (20%) | NA | NA |
   Bucillamine | 5 (17%) | NA | NA |
   Mizoribine | 0 (0%) | NA | NA |
   Gold | 1 (3.3%) | NA | NA |